Video Archives

Micro Ultrasound and MRI of the Prostate

Posted by Gerald L. Andriole, Jr., MD | Oct 2024

Dr. Gerald L. Andriole, Jr., MD, analyzes the evolving role of micro-ultrasound and MRI in the diagnosis and management of prostate cancer and discusses the advancements in imaging technologies that have significantly improved the accuracy of prostate cancer detection.

In this 13-minute talk, Dr. Andriole begins by examining the limitations of utilizing single imaging techniques, particularly in detecting small, clinically significant prostate tumors. Dr. Andriole explores the complementary role of micro-ultrasound and multiparametric MRI (mpMRI) in prostate cancer imaging. This combination of micro-ultrasound and MRI, he notes, enhances the accuracy of prostate cancer diagnosis.

Dr. Andriole also highlights the clinical implications of these imaging modalities and their potential to reduce the need for unnecessary biopsies and more effectively guide active surveillance strategies. He discusses the ongoing research and developments to integrate these technologies into routine clinical practice.

The Association Between Testosterone Treatment and Incident of Cardiovascular Events among Testosterone Deficient U.S. Veterans

Posted by Thomas J. Walsh, MD, MBA, MS | Oct 2024

Thomas J. Walsh, MD, MBA, MS, provides a detailed examination of the relationship between testosterone treatment and the incidence of cardiovascular events among testosterone-deficient U.S. veterans.

In this 19-minute presentation, Dr. Walsh outlines the background of testosterone deficiency, noting ongoing concerns regarding its safety, particularly its potential to increase the risk of heart attacks, strokes, and other heart-related issues.

Drawing on data from a large cohort of U.S. veterans, Dr. Walsh discusses the incidence of cardiovascular events in patients undergoing testosterone therapy compared to those who do not receive such treatment. He discusses the methodology used in the study, including the selection of participants, the duration of follow-up, and the statistical analyses employed to control for confounding variables.

The Battle of Biopsies: Results of a Multi-institutional Randomized Trial of Transrectal vs Transperitoneal Prostate Biopsy

Posted by Mohamad E. Allaf, MD | Oct 2024

Mohammed E. Allaf, MD, delivers a compelling analysis of the outcomes from a multi-institutional randomized trial comparing transrectal and transperitoneal prostate biopsy techniques. This study, which Dr. Allaf presents in detail, addresses a critical question in urological practice: which biopsy method offers the best balance between diagnostic accuracy and patient safety?

Dr. Allaf begins this 21-minute conversation by discussing the historical preference for transrectal prostate biopsy. However, he highlights the growing concerns regarding infection rates and the potential for antibiotic resistance associated with this technique. In contrast, although less commonly used, the transperitoneal approach is posited to reduce the risk of infections and complications.

Management of Late Complications after Continent Urinary Diversion: Case Presentations

Posted by Fiona C. Burkhard, MD | Oct 2024

Fiona C. Burkhard, MD, presents an in-depth analysis of the management of late complications following continent urinary diversion, using case presentations to illustrate key challenges and approaches.

In this 18-minute talk, Dr. Burkhard discusses the most common late complications, including metabolic disturbances, stone formation, and stricture development. Her case presentations vividly demonstrate how these complications can manifest in diverse ways. She provides detailed accounts of surgical and non-surgical treatment options.

Management of Small Renal Tumors: A Guidelines Based Approach

Posted by Mohamad E. Allaf, MD | Oct 2024

Mohammed E. Allaf, MD, presents a comprehensive overview of managing small renal tumors, focusing on a guidelines-based approach that integrates the latest evidence and expert consensus in the evolving landscape of renal tumor management.

In this 20-minute presentation, Dr. Allaf outlines the current guidelines for evaluating small renal masses. He highlights the critical factors influencing management choices, including gender, tumor size, location, patient comorbidities, age, and family history.

In discussing treatment options, Dr. Allaf examines active surveillance, radical or partial nephrectomy, and ablative therapies and the indications for each approach. He also touches on future directions in treatment and imaging while emphasizing the benefits of the current guidelines.